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Abstract: Zein was investigated for use as an oral-drug delivery system by loading 
prednisolone into zein microparticles using coacervation. To investigate the adaptability of 
this method to other drugs, zein microparticles were loaded with hydrocortisone, which is 
structurally related to prednisolone; or mesalazine, which is structurally different having a 
smaller LogP and ionizable functional groups. Investigations into the in vitro digestibility, 
and the electrophoretic profile of zein, and zein microparticles were conducted to shed 
further insight on using this protein as a drug delivery system. Hydrocortisone loading into 
zein microparticles was comparable with that reported for prednisolone, but mesalazine 
loading was highly variable. Depending on the starting quantities of hydrocortisone and 
zein, the average amount of microparticles equivalent to 4 mg hydrocortisone, (a clinically 
used dose), ranged from 60–115 mg, which is realistic and practical for oral dosing. 
Comparatively, an average of 2.5 g of microparticles was required to deliver 250 mg of 
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mesalazine (a clinically used dose), so alternate encapsulation methods that can produce 
higher and more precise mesalazine loading are required. In vitro protein digestibility 
revealed that zein microparticles were more resistant to digestion compared to the zein raw 
material, and that individual zein peptides are not preferentially coacervated into the 
microparticles. In combination, these results suggest that there is potential to formulate a 
delivery system based on zein microparticles made using specific subunits of zein that is more 
resistant to digestion as starting material, to deliver drugs to the lower gastrointestinal tract. 
Keywords: maize; microparticles; protein; drug loading; in vitro digestibility; electrophoresis 
 
1. Introduction  
Hydrocortisone (a corticosteroid) and mesalazine are commonly used in the management of 
inflammatory bowel disease (IBD). The two main types of IBD are ulcerative colitis (UC) and Crohn’s 
Disease (CD). Pharmacological management depends on the severity, type of IBD, and the overall goal 
of treatment [1–3]. 
Corticosteroids are used for their anti-inflammatory effects to induce remission during active UC or 
CD, or when UC becomes refractory to first-line treatment [1]. These corticosteroids can be delivered 
intravenously, orally as controlled-release tablets, or locally as rectal foams, suppositories or enemas [2]. 
Corticosteroids are not used to maintain remission due to dose-dependent side effects [1,2]. Delivering 
corticosteroids by using a colon-targeted delivery system may mean that smaller doses can be used for 
a shorter duration of time, which in turn would reduce the dose-related side effects. 
Mesalazine has a different mode of action from corticosteroids and is used to induce remission in 
both UC and CD of mild to moderate severity [3]. It also maintains remission in UC, but this use in 
CD is controversial [3]. Mesalazine is thought to exert its anti-inflammatory effects locally in the large 
intestine [2,3]. It is commonly administered via the oral route with controlled-release tablets or 
granules [2]. One of the strategies used to target the delivery of mesalazine to the large intestine is 
through the use of pro-drugs, which are inactive when administered, but undergo transformation  
in vivo to become active [3]. In mesalazine pro-drugs, mesalazine is linked to a carrier molecule via an 
azo-bond. The azo-bond is cleaved in the large intestine by the microbial enzyme azoreductase, which 
in combination with the reducing environment of the large intestine, leads to release of the active drug 
molecule from its carrier [3–7]. While these mesalazine pro-drugs are used commercially, one problem 
with their use is the dosing regimen. Depending on the mesalazine pro-drug formulation, doses in 
excess of 4 g daily in four divided doses may be used, with side effects more prevalent with higher 
doses [2,3]. Hence, using an alternative method that targets mesalazine delivery to the large intestine 
may reduce the frequency of dosing required, and reduce the large doses used, thereby reducing dose 
related side effects.  
Zein is a protein extracted from corn (Zea mays), and has previously been investigated for its 
potential as an oral drug delivery system. It is of interest as a drug delivery system as it has a 
“generally recognized as safe” food use status [8], and is reportedly resistant to digestion in the 
stomach [9,10]. Zein has been investigated for use as a tablet excipient [11], and formulated into 
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microparticles to control the release of bioactive agents such as essential oils [12], lysozyme [13], and 
prednisolone [14] in conditions simulating the human digestive tract. Zein microparticles have also 
been used to encapsulate abamectin, protecting it from photo-degradation [15]. This photo-stability 
imparted by encapsulation within zein microparticles would be advantageous for mesalazine because it 
is light sensitive [16]. 
One method used to formulate zein microparticles is coacervation, also known as phase  
separation [10,12,14,17]. Coacervation involves dispersing the core material in a solution of the 
coating material. The microparticles are formed when the coating material desolvates, coacervating 
around the core material. Zein microparticles were successfully loaded with prednisolone (a 
corticosteroid) using a coacervation method [14]. Prednisolone loading and loading efficiency were 
improved by varying the starting quantities of zein and prednisolone. Additionally, more vigorous and 
extensive agitation by a vortex mixer compared to a magnetic stirrer increased drug loading and 
loading efficiency [14]. 
This present study aims to investigate the formulation of zein microparticles loaded with 
hydrocortisone compared to loading with mesalazine. Hydrocortisone was selected as it is structurally 
similar to prednisolone. This was to determine if the methods used for formulating zein-prednisolone 
microparticles could be applied to a structurally similar drug. Mesalazine was selected as it is 
structurally different, and has characteristics unlike prednisolone and hydrocortisone. By comparison, 
mesalazine is more soluble in water [18,19], and has ionizable functional groups whereas prednisolone 
and hydrocortisone do not. Mesalazine was therefore used to determine if the microparticle 
formulation method could successfully be applied to drugs with different structures and characteristics. 
Zein microparticles loaded with either hydrocortisone or mesalazine were formulated using an 
optimized method previously reported for prednisolone [14]. The drug loading and loading efficiency 
were compared. To further characterize the zein microparticles as a potential drug delivery system, the 
protein content, in vitro protein digestibility, and protein electrophoretic profile were determined and 
compared to the zein raw material.  
2. Experimental Section 
2.1. Microparticle Formulation 
Zein microparticles encapsulating either hydrocortisone (≥98%, Sigma Aldrich, St. Louis, MO, 
USA), or mesalazine (≥99%, Sigma Aldrich, St Louis, MO, USA) were formulated using coacervation 
from 70% (v/v) ethanol [14]. The core material was dissolved/dispersed in 12 mL of 70% (v/v) ethanol. 
Zein (Sigma Aldrich, St Louis, MO, USA) was added to the hydrocortisone solution or mesalazine 
dispersion, and mixed using a vortex mixer (Zx3, Velp Scientifica, Usmate, Italy) for 1 min. Water 
(MilliQ; 8 mL) was added and the formulation was vortex mixed for a further 2 min to produce 
microparticles, and these were subsequently freeze-dried. Microparticles formulated without the core 
material, or without zein were used as the controls. Samples with mesalazine were wrapped in 
aluminum foil and prepared in a dimmed room to protect them from light. Each formulation of 
microparticles was made in triplicate to assess the variation between each replicate. Reagents were of 
analytical and HPLC grades. 
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2.2. Analysis of Drug Loading in Microparticles and Encapsulation Efficiency 
2.2.1. Hydrocortisone Microparticles 
Freeze-dried microparticles (10 mg) were washed by vortex mixing for 20 s with 1 mL of ethyl 
acetate to remove any non-encapsulated hydrocortisone. The mixture was centrifuged to recover the 
ethyl acetate supernatant. The wash was repeated three times, after which the microparticles and ethyl 
acetate supernatants were dried using a centrifugal vacuum evaporator (Savant RVT400, Thermo 
Fisher Scientific, Waltham, MA, USA). For each sample, the dried microparticles and the 
hydrocortisone extracted by the ethyl acetate were dissolved in 70% (v/v) ethanol. The amount of 
hydrocortisone present in the microparticles, and the amount washed out by ethyl acetate were 
measured using a UV spectrophotometer (U-1900, Hitachi, Tokyo, Japan) at 254 nm. This wavelength 
was determined based on an UV scan (200–500 nm, at 400 nm/min) of zein (0.5 mg/mL), 
hydrocortisone (51 µg/mL), and a combination of zein (0.5 mg/mL) and hydrocortisone (51 µg/mL) in 
70% (v/v) ethanol. A wavelength of 254 nm was appropriate to measure the absorbance of 
hydrocortisone as there was minimal interference from zein (Figure 1). Three 10 mg aliquots were 
measured from each microparticle sample to assess variability in drug loading and loading efficiency 
within each replicate. Calibration curves in the range of 0–33 µg/mL were used to quantify the amount 
of hydrocortisone, with measurements made in triplicate for each sample.  
Figure 1. UV absorbance spectra (200–500 nm) of zein (0.5 mg/mL), hydrocortisone  
(51 µg/mL), and a mixture of zein (0.5 mg/mL) with hydrocortisone (51 µg/mL) in  
70% (v/v) ethanol. 
 
2.2.2. Mesalazine Microparticles 
The method for measuring loading and loading efficiency was adapted for mesalazine because it is 
reported as “practically insoluble” in ethyl acetate [16]. Mesalazine solubility was assessed in different 
solvents (Table 1) to determine an appropriate substitute for ethyl acetate. The solvent pH was adjusted 
using 1 M HCl. An excess of mesalazine was added to 5 mL of solvent, protected from light and  
left to mix on a suspension mixer at 10 °C. After 22 h, it was allowed to re-equilibrate for 2 h at room 
temperature. Excess mesalazine was removed following centrifugation, and the supernatant was 
analyzed using a UV spectrophotometer. Zein had minimal interference on the absorbance of 
mesalazine at 297 nm (Figure 2). This wavelength was determined based on an UV scan (200–500 nm, 
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at 400 nm/min) of zein (0.5 mg/mL), mesalazine (51 µg/mL), and a combination of zein (0.5 mg/mL) 
and mesalazine (51 µg/mL) in 70% (v/v) ethanol. The amount of mesalazine was quantified on the UV 
spectrophotometer at 297 nm using calibration curves in the range of 0–59 µg/mL. 
Table 1. Mesalazine solubility (mg/mL) in different solvents at varying pH and temperature. 
Solvent pH Temperature (°C) Solubility (mg/mL) 
70% (v/v) ethanol 6.5 25 0.81 
70% (v/v) ethanol 6.5 37 1.40 
70% (v/v) ethanol 4.5 25 0.81 
0.01 M HCl 2 25 0.89 
0.1 M HCl 1 25 1.50 
Distilled water 6.5 25 0.80 
Figure 2. UV absorbance spectra (200–500 nm) of zein (0.5 mg/mL), mesalazine  
(51 µg/mL), and a mixture of zein (0.5 mg/mL) with mesalazine (51 µg/mL) in 70%  
(v/v) ethanol. 
 
Mesalazine loading and loading efficiency was analyzed using the method described for 
hydrocortisone microparticles, except 1 mL of ethyl acetate was replaced with 10 mL of water and the 
process took place in a dimmed room. Mesalazine solubility in 70% (v/v) ethanol at 25 °C, and at pH 
4.5 was comparable to that of distilled water (pH 6.5) (Table 1). Its solubility increased with an 
increase in temperature to 37 °C. The observed solubility of mesalazine in distilled water was in 
agreement with that reported in literature, being 0.84 mg/mL at 25 °C, and 1.41 mg/mL at 37 °C [20]. 
Reducing the pH to 1 also improved solubility [20]. However, the macrostructure of zein 
microparticles we formulated at pH 1 appeared hard and crystalline, as opposed to the soft coarse 
powder formed using a more neutral pH of 6.5 although the structure of zein is reportedly not affected 
in environments above pH 1 [21]. Therefore, distilled water at 25 °C was selected to replace ethyl 
acetate in the wash step due to convenience and ease of use, and because water dissolved mesalazine 
but not zein. The water supernatant from the washes and microparticle pellets were freeze-dried. The 
amount of mesalazine was quantified as above. 
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2.3. Calculating Drug Loading into Microparticles and Encapsulation Efficiency 
Drug loading, i.e., the amount of drug contained within the microparticles, and loading efficiency, 
i.e., the amount of encapsulated drug as a proportion of the amount added initially, were calculated 
using the following two equations.  
Drug loading ሺw/w%ሻ = Amount of drug in microparticles
Amount of microparticles
 × 100 (1)
Loading efficiency ሺw/w%ሻ = Amount of drug in microparticles
Amount of drug initially added
 × 100 (2)
2.4. Particle Size Distribution 
The particle size distribution of the freeze dried microparticles was determined via laser diffraction 
using a Mastersizer 2000E and a small volume sample dispersion unit (Malvern Instruments Ltd., 
Malvern, UK). Freeze dried microparticles (50 mg) were added to 50 mL of 40% ethanol, and 
sonicated for 30 min until the protein was well dispersed. The refractive index of 1.45 was used for 
zein and 1.36 for ethanol. The obscuration range was between 10% and 20% with a residual of less than 
1%. Particle size was measured in duplicate for each sample.  
2.5. Protein Determination 
Nitrogen content of zein and zein microparticles (empty) was determined in triplicate using the 
Dumas combustion method (AACC Standard Method 46–30) [22], then protein content was calculated 
as nitrogen × 6.25. 
2.6. In Vitro Protein Digestibility 
Protein digestibility was measured using an in vitro digestibility assay for cereal proteins which 
included incubating the samples with pepsin at pH 2, then quantifying the nitrogen content of the 
undigested fraction [23]. Incubation time was limited to 1 h to prevent complete digestion of all 
samples [24], to allow subtle differences between the digestibility of the zein compared to the resulting 
microparticles to be identified. Triplicate samples (100 mg) were weighed into pre-dried and  
pre-weighed 50 mL centrifuge tubes, and vortex mixed for 1 min with 35 mL of freshly prepared 
pepsin solution (1.5 mg/mL in 0.1 M phosphate buffer at pH 2). A reagent blank tube was also 
prepared. All tubes were incubated for 60 min at 37 °C in a water bath (OLS200, Grant Instruments, 
Cambridge, UK) shaking at 100 cycles/min. After 60 min, 2 M NaOH (2 mL) was added to each tube, 
then centrifuged at 4900g at room temperature for 20 min. The supernatant containing the digested 
protein was discarded, while the pellets of undigested protein were washed with 20 mL of 0.1 M 
phosphate buffer (pH 7) to remove entrapped digested protein, and centrifuged as above. This washing 
and centrifuging was then repeated, and the resulting pellets were dried overnight in an oven at 60 °C. 
The weight of the dried pellet was calculated from the final weight of the dried pellet and tube. The 
nitrogen content of a known mass of the dried pellet was determined by the Dumas combustion 
method as above and protein digestibility was calculated based on nitrogen content data using the 
following equation: 
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In vitro protein digestibility (%)= Nitrogen (mg) in original sample - Undigested nitrogen in total pellet (mg)
Nitrogen (mg) in original sample
 × 100 (3) 
2.7. Reducing Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Samples (5 mg) were dissolved in 1 mL of 0.0125 M borate buffer (pH 10) containing 1% SDS and 
2% 2-mercaptoethanol by vortex mixing for 5 min, then centrifuged for 5 min at 12,900g at room 
temperature [25–27]. The protein extract supernatants (5 µL) were mixed with 10 µL of loading buffer 
(NuPAGE LDS, Invitrogen, Carlsbad, CA, USA), heated at 95 °C for 5 min, then 10 µL of each sample 
solution was loaded in a precast 4%–15% polyacrylamide SDS-PAGE gel (TGX Mini Gels, BioRad 
Laboratories Inc, Hercules, CA, USA). The gel was electrophoresed in Tris/Glycine buffer (BioRad 
Laboratories Inc, Hercules, CA, USA) at 200 V for 25–30 min at room temperature using a Mini Protean 
system (BioRad Laboratories Inc, Hercules, CA, USA) until the pre-stained molecular weight marker 
proteins were clearly separated and the dye was within 1 cm of the bottom of the gel. The gel was then 
washed three times, for 5 min each, in deionized water, stained with Coomasie Stain (BioRad Laboratories 
Inc, Hercules, CA, USA) for 1.5 h, then washed with several changes of deionized water for 2 h. Gels 
were scanned using a BioRad BioScan Image analyzer (BioRad Laboratories Inc., Hercules, USA).  
2.8. Statistical Analysis 
One-way ANOVA with a Bonferroni post hoc test were used to compare the mean drug loading, 
loading efficiency, and the amount of microparticles required to encapsulate a clinically relevant dose 
of each drug (hydrocortisone or mesalazine). Mean values for protein content, and in vitro protein 
digestibility were compared by applying an unpaired t-test with GraphPad Prism 5.04 (GraphPad 
Software, San Diego, CA, USA). The level of significance was set as p < 0.05, and the coefficient of 
variation (%CV) was calculated to compare the variance between and within replicates of samples. 
3. Results and Discussion  
3.1. Drug Loading and Loading Efficiency 
Hydrocortisone and mesalazine could successfully be loaded into zein microparticles. Increasing the 
starting quantities of zein and hydrocortisone at a constant ratio increased hydrocortisone loading and 
loading efficiency (Table 2). Drug loading was unchanged while loading efficiency increased when 
400 mg of zein was formulated with decreasing quantities of hydrocortisone; most notably when less 
than 100 mg of hydrocortisone was used (Table 2). Depending on the starting quantities of 
hydrocortisone and zein, the average amount of microparticles equivalent to 4 mg hydrocortisone, a 
clinically used dose, ranged from 60 to 115 mg (Figure 3). Hydrocortisone, which closely resembles 
prednisolone in structure, showed similar trends in terms of drug loading and loading efficiency as 
previously reported for prednisolone [14]. Particle size for prednisolone microparticles [14]  
and hydrocortisone microparticles (d(v,0.1) = 0.442 µm, d(v,0.5) = 1.011 µm, d(v,0.9) = 11.305 µm,  
D[3,2] = 0.919 µm, D[4,3] = 4.163 µm) were also very similar. These similarities may be explained by the 
similar properties that prednisolone and hydrocortisone possess due to their related structures (Table 3).  
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Table 2. Drug loading and loading efficiency (mean ± SEM) into zein microparticles 
formulated using various combinations of zein and hydrocortisone, with the coefficient of 
variation (%CV) for within and between replicates. One-way factorial ANOVA with a  
post hoc Bonferroni multiple comparisons test was used to compare selected means (p < 0.05). 
Zein (mg) Drug (mg) Ratio 
%CV Total 
mean ± SEM 
Total 
%CV Rep 1 Rep 2 Rep 3 
Hydrocortisone loading (w/w%) 
800 200 4 7.71 15.43 3.01 5.41 ± 0.60 a 19 
600 150 4 7.41 2.97 1.90 4.72 ± 0.05 ab 2 
200 50 4 5.66 3.98 21.67 2.84 ± 0.25 b 16 
400 200 2 1.07 7.36 6.37 2.69 ± 0.08 x 5 
400 150 2.7 5.25 4.87 7.98 3.68 ± 0.86 x 40 
400 100 4 10.11 1.95 9.44 3.31 ± 0.20 b,x 11 
400 50 8 3.11 8.16 8.49 3.66 ± 0.28 x 13 
400 25 16 2.18 25.09 11.25 3.77 ± 0.44 x 20 
Hydrocortisone loading efficiency (w/w%) 
800 200 4 6.66 12.64 3.42 33.13 ± 4.55 A 24 
600 150 4 4.28 2.80 2.38 27.47 ± 2.28 AB 14 
200 50 4 8.31 1.56 27.00 16.03 ± 1.38 B 15 
400 200 2 4.40 10.47 11.18 9.44 ± 0.17 X 3 
400 150 2.7 5.53 1.48 19.01 14.54 ± 2.63 X 31 
400 100 4 26.98 7.51 19.66 20.66 ± 0.39 B,X 3 
400 50 8 5.16 6.05 4.27 40.55 ± 1.64 Y 7 
400 25 16 1.98 3.78 1.27 84.18 ± 2.40 Z 5 
Means were grouped as follows for statistical analysis, with the means that were not significantly different at p < 0.05 
assigned the same letter: varying quantities with constant ratio of zein and hydrocortisone (a–b, A–B), constant quantity 
of zein with varying hydrocortisone quantity (x, X–Z). 
Figure 3. The amount of zein-hydrocortisone microparticles (mean ± SEM; n = 3) 
equivalent to a clinically used dose of hydrocortisone (4 mg) for samples prepared using 
various combinations of hydrocortisone (25–200 mg) and zein (200–800 mg). One-way 
factorial ANOVA with a post hoc Bonferroni test was used to compare selected means for 
varying quantities with constant ratio of zein and mesalazine (a–b), and a constant quantity 
of zein with varying mesalazine quantity (x). The level of significance was set at p < 0.05 
and means that were not significantly different were assigned the same letter. 
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Table 3. The molecular structure, pKa, LogP, aqueous solubility, and solubility in ethanol 
of prednisolone, hydrocortisone and mesalazine. 
 Prednisolone Hydrocortisone Mesalazine 
Molecular structure 
pKa - - 2.15, 7.10, 12.30 [20] 
Log P 1.62 [28] 1.61 [28] 0.64 [18] 
Aqueous solubility  
at 25 °C 
0.273 mg/mL [19] 0.311 mg/mL [19] 1.85 mg/mL [18] 
Solubility in  
absolute ethanol 
24.3 mg/mL  
at 25 °C [19] 
14.7 mg/mL  
at 25 °C [19] 
0.324 mg/mL  
at 24 °C [29]  
Conversely, mesalazine, which is structurally very different and has different properties compared 
to prednisolone and hydrocortisone (Table 3), did not produce similar drug loading and loading 
efficiency trends. General trends were visible in mesalazine loading and loading efficiency but the 
extremely high variation between the replicates meant that a statistical difference was not observed 
(Table 4). When the ratio of drug to protein was kept constant, the mesalazine loading and loading 
efficiency into the zein microparticles appeared to be most improved with the larger starting quantities 
of 200 mg mesalazine and 800 mg zein (Table 4). A constant amount of zein (400 mg) with increasing 
quantities of mesalazine appeared to increase drug loading and loading efficiency. However, these 
trends lack statistical significance due to large differences between the three replicates prepared for 
each zein-mesalazine combination (Table 4). Nonetheless, the loading efficiency for the combination 
of 400 mg zein and 150 mg mesalazine was significantly higher than the combination with 25 mg 
mesalazine. Using the combination with the highest drug loading (i.e., 400 mg zein and 150 mg 
mesalazine), an average of approximately 2.5 g of microparticles was equivalent to 250 mg of 
mesalazine, which is a clinically used dose (Figure 4). A large gelatin capsule (size 000) that is 
administered orally has a capacity of 822–1644 mg depending on the density of the contents used to 
fill the capsule [30], meaning that the amount of microparticles required to deliver a clinically relevant 
dose of mesalazine is 1.5 to 3-fold more than the capacity of a size 000 gelatin capsule. Particle size  
of mesalazine microparticles (d(v,0.1) = 1.381 µm, d(v,0.5) = 5.047 µm, d(v,0.9) = 12.730 µm,  
D[3,2] = 3.322 µm, D[4,3] = 6.154 µm) indicated that they were larger in size than the hydrocortisone, 
and prednisolone microparticles. 
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Table 4. Drug loading and loading efficiency (mean ± SEM) into zein microparticles 
formulated using various combinations of zein and mesalazine, with the coefficient of 
variation (%CV) for within and between replicates. One-way factorial ANOVA with a  
post hoc Bonferroni multiple comparisons test was used to compare selected means (p < 0.05). 
Zein (mg) Drug (mg) Ratio 
%CV Total  
mean ± SEM 
Total  
%CV Rep 1 Rep 2 Rep 3 
Mesalazine loading (w/w%) 
800 200 4 6.79 14.67 10.02 4.84 ± 3.38 a 121 
600 150 4 8.61 26.28 4.21 4.66 ± 2.34 a 87 
200 50 4 5.98 13.9 42.02 4.09 ± 1.54 a 65 
400 200 2 19.05 5.91 1.57 8.02 ± 1.87 x 41 
400 150 2.7 12.18 7.69 11.04 9.70 ± 2.84 x 51 
400 100 4 1.58 4.25 2.41 2.91 ± 0.98 a,x 59 
400 50 8 5.90 28.59 19.78 2.21 ± 0.77 x 60 
400 25 16 17.96 ND ND 0.14 ± 0.14 x ND 
Mesalazine loading efficiency (w/w%) 
800 200 4 7.60 12.78 3.38 33.65 ± 15.90 A 82 
600 150 4 11.39 19.19 11.90 23.37 ± 13.33 A 99 
200 50 4 4.77 12.80 37.06 24.71 ± 4.23 A 30 
400 200 2 8.08 3.02 3.19 40.08 ± 4.77 X,Y 21 
400 150 2.7 6.00 4.31 8.59 61.69 ± 9.61 X 27 
400 100 4 2.74 12.66 22.48 20.97 ± 4.75 A,XY 39 
400 50 8 2.12 28.00 11.20 21.57 ± 7.79 XY 63 
400 25 16 15.49 ND ND 2.73 ± 2.73 Y ND 
Means were grouped as follows for statistical analysis, with the means that were not significantly different at p < 0.05 
assigned the same letter: varying quantities with constant ratio of zein and mesalazine (a, A), constant quantity of zein 
with varying mesalazine quantity (x, X–Y). ND: %CV could not be calculated as no mesalazine loading was observed. 
Figure 4. The amount of zein-mesalazine microparticles (mean ± SEM; n = 3) equivalent 
to a clinically used dose of mesalazine (250 mg) for samples prepared using various 
combinations of mesalazine (25–200 mg) and zein (200–800 mg). One-way factorial 
ANOVA with a post hoc Bonferroni test was used to compare selected means (varying 
quantities with constant ratio of zein and mesalazine, and a constant quantity of zein with 
varying mesalazine quantity). The means were not significantly different at p < 0.05. 
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The overall %CV in the zein microparticles formed with mesalazine (loading 41%–121%, loading 
efficiency 21%–99%; Table 4), was generally larger than that of hydrocortisone (loading 2%–40%, 
loading efficiency 3%–31%; Table 2), indicating a lack of reproducibility in loading mesalazine into 
the zein microparticles using this formulation method. Drug loading and loading efficiency of both 
hydrocortisone and mesalazine was more reproducible within each sample, than between samples, as 
the %CV within each set of replicates (three sub-samples were measured for each set of microparticles 
that were prepared) was generally smaller than that between replicates. The more variable mesalazine 
loading into zein microparticles, compared to hydrocortisone, might be explained by the different 
chemical structures. Hydrocortisone is a steroid consisting of a five-membered ring, and three  
six-membered rings with no ionizable groups. Mesalazine consists of a single ring structure with three 
ionizable groups (carboxyl, amine and hydroxyl groups). The pKa of these ionizable groups are 2.15, 
7.10 and 12.30 respectively [20], so at a neutral pH, the carboxyl group would be ionized with a 
negative charge, the amine group partially ionized with a positive charge, and the hydroxyl group 
would be unionized. Hence, during the formulation of the microparticles in 70% (v/v) ethanol, some of 
the mesalazine molecules would exist as zwitterions, i.e., ionized with both a positive and negative 
charge. The presence of both these charges on some mesalazine molecules may have interfered with 
the inter-molecular interactions involved in the formation of zein microparticles during the 
coacervation process. Zein is amphiphilic in character [31], and self-arranges into micelle-like 
aggregates [32]. In the presence of other particles, zein forms small aggregates with the hydrophobic 
zein moieties facing the hydrophobic particles when water is added; and aggregates with the 
hydrophilic zein moieties facing the hydrophilic particles when ethanol is added [31,32]. During the 
formation of zein-hydrocortisone microparticles, the hydrophobic nature of hydrocortisone would have 
helped to promote the formation of these micelle-like structures by interacting with the hydrophobic 
zein moieties. Furthermore, hydrocortisone lacks ionizable groups to interfere with the formation of 
these micelle-like structures. Conversely, when the comparatively less hydrophobic mesalazine was 
loaded, the negatively charged mesalazine and those present as zwitterions may have caused zein to 
use different molecular arrangements [31] to accommodate the differently charged mesalazine 
molecules. This, in conjunction with the different mesalazine charges, gives rise to inter- and  
intra-molecular repulsions during the assembly of these micelle-like structures, causing erratic and 
non-reproducible loading. Mesalazine is not considered a hydrophilic compound per se, but its less 
hydrophobic and charged nature compared to prednisolone and hydrocortisone may mean that adding 
ethanol to the zein-mesalazine dispersion (as opposed to water described herein) might result in 
improved loading. This is because ethanol will cause the hydrophobic moieties in zein to be orientated 
towards the solvent, and the hydrophilic moieties to be oriented toward the mesalazine molecule, 
which may facilitate the formation of zein-meslazine microparticles [32]. Preliminary results from 
microparticles formulated by adding pure ethanol to the zein-mesalazine dispersion (400 mg zein and 
100 mg mesalazine) also resulted in variable, albeit higher mesalazine loading and loading efficiency. 
Mesalazine loading was 29.34% ± 7.12% (%CV = 42.04%), and loading efficiency was 53.03% ± 
3.10% (%CV = 10.14); mean ± SEM; unpublished data. Hence, future studies could further investigate 
this method of formulating zein-mesalazine microparticles.  
The variability observed between the replicates of mesalazine loaded microparticles might also be 
due to the method of agitation used during the coacervation process. More vigorous and extensive 
Pharmaceutics 2013, 5 288 
 
 
mixing provided by a vortex mixer improved drug loading, as was noted with loading prednisolone 
into zein microparticles [14], but the use of a vortex mixer may have contributed to the variability. 
This is because there was a brief time lapse where the mixture could not be agitated between removing 
and replacing the lid of the centrifuge tube when water was added to induce coacervation. This 
temporary stasis in the mixture may have allowed mesalazine to settle in solution, such that when 
microparticles were formed with coacervation, varied amounts of mesalazine were encapsulated. 
Hence, an alternative method of mixing that provides continuous agitation, and more energy to the 
solution (e.g., a magnetic stirrer or a sonicator probe), may in fact help to keep the mesalazine particles 
evenly dispersed and suspended while zein is deposited around it.  
Compared to hydrocortisone and prednisolone, mesalazine is more soluble in water and less soluble 
in 70% (v/v) ethanol (Tables 1 and 5) [19,20]. As such, higher drug loading values were expected for 
mesalazine-loaded microparticles than hydrocortisone-loaded microparticles, as saturating the aqueous 
phase with the core material reportedly allows for improved encapsulation [33,34]. Similarly, the 
mesalazine being dispersed rather than dissolved in the 70% (v/v) ethanol was also thought to  
improve drug loading as the dispersed drug particles would form a core on which the zein could  
coacervate. However, large variability in drug loading and loading efficiency between replicates of the  
zein-mesalazine microparticles makes this comparison difficult. 
The solubility of mesalazine is improved at the extremes of pH, where one ionized species 
dominates [20]. While such pH environments may not be ideal for formulating zein microparticles, an 
alternative coating material that is compatible at such a pH may still be used to form microparticles 
with mesalazine. The presence of only one charge, together with an increase in solubility may assist 
mesalazine loading into microparticles with more reproducibility using a simple coacervation process 
like the one described herein. Mesalazine may also be loaded into microparticles using a method 
similar to complex coacervation, which involves the use of charged coating materials [35,36]. 
The sensitivity of mesalazine to heat and light makes it difficult to improve its solubility using 
conventional methods (e.g., increasing temperature). Given these constraints, it is difficult to 
reproducibly formulate zein-mesalazine microparticles with high drug loading, high loading efficiency, 
and with precision using a simple coacervation method. As such, another method of encapsulation that 
can accommodate the restrictions imposed by the low solubility of mesalazine in ethanol, along with 
light and heat sensitivities, may have more success in formulating zein microparticles loaded with 
higher levels of mesalazine. Methods such as spray chilling may be applicable. Spray chilling is 
similar to spray drying except it is suitable for heat sensitive material because cooled or chilled air  
are used [37,38]. 
3.2. Protein Content and in Vitro Protein Digestibility 
The protein content of the zein raw material was consistent with previous reports that it was not 
100% pure protein [39,40]. Neither the zein raw material nor the resulting empty zein microparticles 
that were not loaded with drug were 100% pure protein, with the protein content of the zein starting 
material being significantly higher than the empty zein microparticles (Table 5). The empty zein 
microparticles were of even lower protein content, possibly due to artifacts of the microparticle 
formulation process, but these components were not quantified in the present study. The in vitro 
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protein digestibility of the empty zein microparticles was significantly lower than the zein raw 
material. The amphiphilic nature of zein makes it thermodynamically favorable for the zein to  
self-assemble into colloid/micelle like structures [31,41]. Hence, this more stable structure of the 
microparticles may be more resistant to digestion compared to the zein raw material. Empty zein 
microparticles may have potential as an oral delivery system that targets the lower gastrointestinal tract 
e.g., as tablet coating, or using empty zein microparticles as a tablet excipient. 
Table 5. Protein content and in vitro protein digestibility of zein and empty zein 
microparticles. Values are mean ± standard deviation (n = 3). Means within a column that 
were not significantly different at p < 0.05 were assigned the same letter: protein content 
(A,B), and in vitro protein digestibility (a,b). 
Sample Protein content (g/100 g) In vitro protein digestibility (%) 
Zein (raw material) 85.4 ± 0.4 A 93.3 ± 2.2 a 
Zein microparticles (empty) 82.9 ± 1.0 B 50.3 ± 5.8 b 
3.3. Reducing Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
The electrophoretic profile of the zein starting material, and the resulting empty microparticles were 
similar, with both having two major bands present at 20 kDa, and a third at 40 kDa (Figure 5), 
suggesting that individual zein peptides were not preferentially coacervated into the microparticles 
(Figure 5). The two major bands present at 20 kDa are likely to represent the major subunits of α-zein 
(21–25 kDa) which account for approximately 80% of total zein [42]. Other minor protein classes are 
β-zein (10% of the total zein, 17–18 kDa), and γ-zein (10% of the total zein, approximately 27 kDa) [42]. 
Accordingly, this suggests that the band at 40 kDa is neither β-zein nor γ-zein, but a dimer of the  
α-zein peptides. While γ-zein was not visible on the gel (Figure 5), likely due to its low concentrations, 
it is known to be most resistant of the zein peptides to digestion [43]. Therefore, zein protein from 
maize varieties with higher levels of γ-zein may be useful for the development of microparticles for 
drug delivery to the lower gastrointestinal tract. 
Figure 5. SDS-PAGE of zein and empty zein microparticles extracted with borate buffer 
under reducing conditions. (1) MW standards; (2), (3) zein; (4), (5) empty zein 
microparticles. Clear arrow, and solid arrow are peptides c. 20 kDa; solid diamond are 
peptides c. 40 kDa. 
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4. Conclusions  
Hydrocortisone and mesalazine can successfully be formulated into microparticles with zein using 
coacervation. The amount of microparticles required for a clinical dose of hydrocortisone is  
realistic and practical. If this zein delivery system for hydrocortisone is resistant to the digestive 
processes of the stomach and small intestine, it may offer benefits over the commercially available 
immediate-release hydrocortisone tablets. However, given the large doses of mesalazine used 
clinically, the amount of microparticles required for a dose of mesalazine is not practical. This, in 
conjunction with the lack of reproducibility in mesalazine loading into the zein microparticles using 
this formulation method, precludes its usefulness in a clinical setting. Hence, loading mesalazine into 
zein requires further investigation to produce higher drug loading yields with more precision. Further 
investigations include assessing an alternate method of encapsulation, or a modified version of the 
methods described herein, e.g., increasing the ethanol concentration to induce coacervation and using a 
magnetic stirrer for a continuous source of agitation. A method that can reproducibly formulate zein 
microparticles with high mesalazine loading means that zein may have more success as an  
orally delivered, delayed or controlled-release drug delivery system for mesalazine. In vitro protein 
digestibility and electrophoretic profiles of zein microparticles (compared to the raw material) suggest 
there is potential to formulate a delivery system to deliver drugs to the lower gastrointestinal tract, 
based on zein microparticles made using specific subunits of zein that is more resistant to digestion. 
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